Close Menu

Sanofi

Sanofi has been hit with a nearly $12 million fine for supporting a charity that covered the costs of co-pays for Medicare patients taking an expensive drug sold by the firm.

This week's news includes Illumina, Becton Dickinson, PerkinElmer, iGene Laboratory, Novacyt, Twist Bioscience, Lustgarten Foundation, and GlaxoSmithKline.

The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.

The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.

Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.

The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.

The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.

Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.